Spots Global Cancer Trial Database for triple negative breast neoplasms
Every month we try and update this database with for triple negative breast neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | NCT02427581 | Triple Negative... Triple Negative... Triple-Negative... | Personalized sy... Poly ICLC | 18 Years - | Washington University School of Medicine | |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | NCT03310957 | Triple Negative... | ladiratuzumab v... Pembrolizumab | 18 Years - | Seagen Inc. | |
| A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | NCT04879849 | Carcinoma, Non-... Triple Negative... Squamous Cell C... | Pembrolizumab TAK-676 Image-guided ra... | 18 Years - | Takeda | |
| Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab | NCT02926196 | Triple Negative... | MSB0010718C | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | NCT03838367 | Triple Negative... | 350 mg leronlim... 525 mg leronlim... 700 mg leronlim... AUC 5 Carboplat... Maximum Tolerat... | 18 Years - | CytoDyn, Inc. | |
| A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | NCT06400472 | Ovarian Neoplas... Endometrial Neo... Uterine Cervica... Carcinoma, Non-... Triple Negative... Pancreatic Neop... Colorectal Neop... | LY4170156 | 18 Years - | Eli Lilly and Company | |
| Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | NCT04561362 | Advanced Solid ... Urinary Bladder... Triple Negative... Carcinoma, Non-... Ovarian Neoplas... | BT8009 Pembrolizumab | 18 Years - | BicycleTx Limited | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | NCT05485766 | Triple Negative... Triple Negative... Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation BRCA Mutation BRCA-Associated... | Pembrolizumab Paclitaxel Carboplatin Olaparib Definitive Surg... | 18 Years - | Okayama University | |
| Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer | NCT04669522 | Triple Negative... | 18 Years - | Pius-Hospital Oldenburg | ||
| A Safety Study of SGN-LIV1A in Breast Cancer Patients | NCT01969643 | HER2 Positive B... Hormone Recepto... Triple Negative... HER2 Mutations ... | ladiratuzumab v... Trastuzumab | 18 Years - | Seagen Inc. | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | NCT04489940 | Triple Negative... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | NCT02632448 | Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc... | LY2880070 Gemcitabine | 18 Years - | Esperas Pharma Inc. | |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | NCT03838367 | Triple Negative... | 350 mg leronlim... 525 mg leronlim... 700 mg leronlim... AUC 5 Carboplat... Maximum Tolerat... | 18 Years - | CytoDyn, Inc. | |
| Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | NCT05020860 | Breast Cancer Breast Neoplasm Breast Cancer F... Breast Cancer I... Breast Cancer S... Breast Cancer S... Triple Negative... Hormone Recepto... HER2-positive B... Triple Negative... Estrogen Recept... | Paclitaxel Carboplatin Trastuzumab Pertuzumab Doxorubicin Cyclophosphamid... Pembrolizumab Pertuzumab/Tras... | 18 Years - | Baylor Breast Care Center | |
| Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC | NCT03997123 | Triple Negative... | Capivasertib Paclitaxel Placebo | 18 Years - 130 Years | AstraZeneca | |
| Triple-negative Breast Cancer: a New Perspective on Biomarkers | NCT03539965 | Triple Negative... Triple Negative... | 18 Years - 80 Years | Instituto Nacional de Cancer, Brazil | ||
| Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | NCT02622074 | Triple Negative... | Pembrolizumab Nab-paclitaxel Anthracycline (... Cyclophosphamid... Carboplatin Paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of AK-01 (LY3295668) in Solid Tumors | NCT03092934 | Neoplasms Neoplasm Metast... Triple Negative... Head and Neck N... Breast Neoplasm... Solid Tumor, Ad... Small Cell Lung... | LY3295668 | 18 Years - | Eli Lilly and Company | |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | NCT02685306 | Breast Cancer Triple Negative... Triple-Negative... Triple-Negative... Triple Negative... ER-Negative PR-... ER-Negative PR-... | Bavituximab Taxane | 18 Years - | Peregrine Pharmaceuticals | |
| A Study of Pembrolizumab and Cryoablation in People With Breast Cancer | NCT06246968 | Metastatic Brea... Breast Cancer Breast Cancer S... Triple Negative... Triple Negative... Metastatic Trip... Locally Advance... Locally Advance... | Pembrolizumab Cryoablation | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of SGN-PDL1V in Advanced Solid Tumors | NCT05208762 | Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer | SGN-PDL1V pembrolizumab | 18 Years - | Seagen Inc. | |
| Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment | NCT05435352 | Triple Negative... Triple Negative... | Core needle bio... | 18 Years - | Ourotech, Inc. | |
| Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study | NCT05067530 | Triple Negative... | Palbociclib Paclitaxel Carboplatin | 18 Years - | Medical University of Gdansk | |
| Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | NCT03225547 | Triple Negative... Breast Cancer | Pembrolizumab Mifepristone | 18 Years - | University of Chicago | |
| A Study of SGN-PDL1V in Advanced Solid Tumors | NCT05208762 | Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer | SGN-PDL1V pembrolizumab | 18 Years - | Seagen Inc. | |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | NCT04504669 | Clear Cell Rena... Non-Small-Cell ... Triple Negative... Squamous Cell C... Small Cell Lung... Gastroesophagea... Melanoma Cervical Cancer Advanced Solid ... | AZD8701 Durvalumab | 18 Years - 101 Years | AstraZeneca | |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | NCT03199040 | Triple Negative... Triple Negative... TNBC - Triple-N... Triple-negative... | Durvalumab Neoantigen DNA ... TDS-IM system (... Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | NCT02720185 | Breast Neoplasm... Triple Negative... | Dasatinib Conventional Su... Laboratory Biom... | 18 Years - | University of Wisconsin, Madison | |
| Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy | NCT02348320 | Triple Negative... Triple-Negative... Triple Negative... | Personalized po... | 18 Years - | Washington University School of Medicine | |
| A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer | NCT03371017 | Triple Negative... | Atezolizumab Placebo Gemcitabine Capecitabine Carboplatin | 18 Years - | Hoffmann-La Roche | |
| Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | NCT06154109 | Triple Negative... | Xiaopi granules Xiaopi decoctio... Placebo | 18 Years - 75 Years | Guangdong Provincial Hospital of Traditional Chinese Medicine | |
| Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | NCT05973864 | Triple Negative... | Pembrolizumab i... Capecitabine ta... Local radiother... | 18 Years - | UNICANCER | |
| "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer | NCT06067061 | Triple Negative... | Atezolizumab + ... | 18 Years - | Institut Curie | |
| Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | NCT06057636 | Breast Cancer Inflammatory Br... Inflammatory Br... Triple Negative... Neoplasm Metast... | Self-Administer... Self-Administer... | 18 Years - 99 Years | The University of Tennessee, Knoxville | |
| Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab | NCT02926196 | Triple Negative... | MSB0010718C | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | NCT03036488 | Triple Negative... | Pembrolizumab Carboplatin Paclitaxel Doxorubicin Epirubicin Cyclophosphamid... Placebo Granulocyte col... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | NCT02685306 | Breast Cancer Triple Negative... Triple-Negative... Triple-Negative... Triple Negative... ER-Negative PR-... ER-Negative PR-... | Bavituximab Taxane | 18 Years - | Peregrine Pharmaceuticals | |
| Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer | NCT06365788 | Triple Negative... | Abemaciclib Bicalutamide | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | NCT03199040 | Triple Negative... Triple Negative... TNBC - Triple-N... Triple-negative... | Durvalumab Neoantigen DNA ... TDS-IM system (... Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | NCT04561362 | Advanced Solid ... Urinary Bladder... Triple Negative... Carcinoma, Non-... Ovarian Neoplas... | BT8009 Pembrolizumab | 18 Years - | BicycleTx Limited | |
| NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | NCT04335669 | Breast Cancer Triple Negative... | epirubicin, cyc... epirubicin, cyc... | 18 Years - 75 Years | Lund University Hospital | |
| A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | NCT04879849 | Carcinoma, Non-... Triple Negative... Squamous Cell C... | Pembrolizumab TAK-676 Image-guided ra... | 18 Years - | Takeda | |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | NCT03199040 | Triple Negative... Triple Negative... TNBC - Triple-N... Triple-negative... | Durvalumab Neoantigen DNA ... TDS-IM system (... Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | NCT06057636 | Breast Cancer Inflammatory Br... Inflammatory Br... Triple Negative... Neoplasm Metast... | Self-Administer... Self-Administer... | 18 Years - 99 Years | The University of Tennessee, Knoxville | |
| Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | NCT03692689 | Triple Negative... | SCT200 | 18 Years - 75 Years | Sinocelltech Ltd. | |
| A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors | NCT06157892 | Breast Neoplasm... Gastroesophagea... HER2 Low Breast... HER2 Positive B... Stomach Neoplas... Triple Negative... | disitamab vedot... tucatinib | 18 Years - | Seagen Inc. | |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | NCT02632448 | Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc... | LY2880070 Gemcitabine | 18 Years - | Esperas Pharma Inc. | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | NCT03692689 | Triple Negative... | SCT200 | 18 Years - 75 Years | Sinocelltech Ltd. | |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | NCT02632448 | Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc... | LY2880070 Gemcitabine | 18 Years - | Esperas Pharma Inc. | |
| A Safety Study of SGN-LIV1A in Breast Cancer Patients | NCT01969643 | HER2 Positive B... Hormone Recepto... Triple Negative... HER2 Mutations ... | ladiratuzumab v... Trastuzumab | 18 Years - | Seagen Inc. | |
| Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | NCT06385990 | Triple Negative... | UTD1 | 18 Years - 70 Years | Hunan Cancer Hospital | |
| Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | NCT03818685 | Breast Cancer Triple Negative... | Nivolumab Ipilimumab Capecitabine | 18 Years - | Centre Leon Berard | |
| Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | NCT04489940 | Triple Negative... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | NCT03396445 | Pharmacokinetic... Solid Tumor Carcinoma, Non-... Triple Negative... | Boserolimab Pembrolizumab Pemetrexed Carboplatin Nab-paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | NCT06385990 | Triple Negative... | UTD1 | 18 Years - 70 Years | Hunan Cancer Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
